ArticleMedical oncology (Northwood, London, England)2025
Derazantinib enhances gemcitabine efficacy in PDAC by attenuating the NF-κB and MAPK pathways to suppress MUC5AC expression.
Wenkai Ye et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.